Drugs by active ingredient

Monthly reports by species, five years

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

2025 covers reports received through March 2026 only.

Signs listed in reports

share of pyrantel tartrate reports listing the termall horse reports

1. Accidental exposure[exposure that was not intended]20.2%207
2. No sign[no clinical sign was reported]14.7%150
3. Ineffective, strongyles[legacy FDA term: the product did not have the expected effect (strongyles)]12.7%130
4. Abdominal pain10.4%106
5. Containers, Abnormal[a product quality report, not a sign in an animal]9.8%100
6. Seal, Abnormal[a product quality report, not a sign in an animal]8.7%89
7. Ineffective, worms NOS[legacy FDA term: the product did not have the expected effect (worms nos)]6.9%71
8. Ineffective, parasite(s) NOS[legacy FDA term: the product did not have the expected effect (parasite(s) nos)]6.2%63
9. Depression[dull, quiet or withdrawn]4.2%43
10. Diarrhoea[diarrhea]3.9%40
11. Death3.7%38
12. Anorexia[not eating]3.1%32
13. Ineffective, ascarids NOS[legacy FDA term: the product did not have the expected effect (ascarids nos)]2.8%29
14. Weight loss2.7%28
15. Contamination, Mold2.6%27
16. Containers, Damaged[a product quality report, not a sign in an animal]2.2%22
17. Death by euthanasia[the animal was euthanized]2.1%21
18. Vomiting2.1%21
19. Digestive tract disorder NOS[digestive problem, type not specified]2%20
20. Lack of efficacy (endoparasite) - Cyathostominae[the product did not have the expected effect: Cyathostominae]1.9%19
21. Unpalatable[legacy FDA term: the animal would not take it]1.8%18
22. Urticaria[hives]1.7%17
23. Lack of efficacy - NOS[the product did not have the expected effect]1.6%16
24. Anaemia NOS[low red blood cell count]1.5%15
25. Loss of condition1.5%15
26. Product Defect, General[a product quality report, not a sign in an animal]1.5%15
27. Vials, Leaking[a product quality report, not a sign in an animal]1.5%15
28. Behavioural disorder NOS[behaviour change, type not specified]1.4%14
29. Hair modification NOS[NOS: not otherwise specified]1.4%14
30. Colic1.3%13

Top 30 of 265 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Coloured bar: reports naming pyrantel tartrate. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Route of administration stated in reports: oral (807), topical (2).

In context

This set accounts for 100% of all reports naming pyrantel tartrate, so no separate ingredient column is shown. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.